Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors.

PARP inhibition breast neoplasms ovarian neoplasms pancreatic neoplasms prostatic neoplasms somatic BRCA1/2

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
06 Mar 2024
Historique:
received: 29 12 2023
revised: 28 02 2024
accepted: 05 03 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

Ten percent of patients with breast cancer, and probably somewhat more in patients with ovarian cancer, have inherited germline DNA mutations in the breast and ovarian cancer genes

Identifiants

DOI: 10.3390/biomedicines12030593 PMID: 38540206
pubmed: 38540206
pii: biomedicines12030593
doi: 10.3390/biomedicines12030593
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Semmelweis University
ID : APC coverage

Auteurs

Gyongyver Szentmartoni (G)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.

Dorottya Mühl (D)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.

Renata Csanda (R)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.

Attila Marcell Szasz (AM)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
ORCID: 0000-0003-2739-4196

Zoltan Herold (Z)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
ORCID: 0000-0001-5990-4889

Magdolna Dank (M)

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
ORCID: 0000-0002-4694-3624

Classifications MeSH